Opiant Pharmaceuticals — Investor Presentation (September 2017)
39 slides from Opiant Pharmaceuticals's investor presentation, Sep 12, 2017
Slide 1: Focused on Addiction
FOCUSED ON ADDICTION Company Presentation September 2017 NASDAQ: OPNT
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation contains ‘forward - looking statements’ within the meaning of Section of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These forward - looking statements relate to future events or our future fi
Slide 3: OPNT: Focused on Addiction
3 OPNT: Focused on Addiction A Commercial - Stage Specialty Pharma Company Focused on Addiction Leveraging expertise, technology and a record of success to address the leading sources of addiction • Opioids • Alcohol • Food
Slide 4: Lead Programs
4 Lead Programs Indication Product Candidate / Regulatory Pathway Pre - clinical Phase 1 Phase 2 Phase 3 NDA FDA Approval Partner Opioid Overdose NARCAN® Nasal Spray 505(b)(2) Eating Disorders OPNT001 Opioid Antagonist Nasal Spray 505(b)(2) Alcohol Dependence OPNT002 Opioid Antagonist Nasal Spray /
Slide 5: Management Team
Arvind Agrawal MSc EVP, Medical Affairs Extensive addiction and CNS drug development experience Dr. Roger Crystal MD MRCS MBA Chief Executive Officer David O’Toole , CPA Chief Financial Officer Mark Ellison, Ph.D. EVP Development, Manufacturing and Quality Dr. Phil Skolnick Ph.D D.Sc hon C
Slide 6: Opiant aims to become a leading addiction biopharma
Opiant aims to become a leading addiction biopharma developing drugs at low cost, and quick to market Replicate recent success Invest long term Deliver on first program • New programs • predominantly 505(b)(2), relatively low cost , low technical risk • primarily using nasal opioid antagonists • Lar
Slide 7: Addressing Addiction
Addressing Addiction @ Opiant
Slide 8: Addiction has evolved as a disease, now more acceptable to treat with pharmacotherapy
8 Addiction has evolved as a disease, and now more acceptable to treat with pharmacotherapy The Past: Addicts as “junkies”; The Present: Addiction now recognized as a brain disease The Future: Incorporate pharmacotherapy as standard of care
Slide 9: Addiction now represents an attractive commercial opportunity
Addiction now represents an attractive commercial opportunity 9 Strong sales from existing products • Suboxone sales > $1B • 27% growth in Vivitrol sales expected for 2017 - $250M Significant unmet need & increased government funding • Only 1 in 9 addicts receive appropriate treatment • Problem grow
Slide 10: Addictions driven by reward center dopamine, blocked by opioid antagonists
10 Addictions are driven by the brain’s reward center releasing dopamine which can be blocked by opioid antagonists
Slide 11: Opioid antagonists act on breathing and reward centers
Opioid antagonists acts on both the brain’s breathing and reward centers 11 Prior to OPNT001 2 time points after nasal administration of OPNT001
Slide 12: Opioid antagonists validated as therapeutics with excellent safety profile
12 Opioid antagonists have been validated as therapeutics with an excellent safety profile
Slide 13: NARCAN Nasal Spray
NARCAN® Nasal Spray @ Opiant
Slide 14: Opioid addiction and overdose: a significant public health crisis
14 Opioid addiction and overdose: A significant public health crisis • Opioid overdose deaths have increased dramatically since 2000 • Dramatic increase in synthetic opioids including fentanyl • Approximately opioid 33,000 overdose deaths in 2015
Slide 15: Rise in overdose cases from more potent, longer lasting opioids
A major issue is the rise in overdose cases from opioids more potent and longer lasting than heroin 15 Increasing overdose rates from 1. more potent opioids 2. longer acting opioids
Slide 16: Naloxone saves lives if given quickly
16 Naloxone saves lives if given quickly – injections can only be given by qualified personnel Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid pain killers, heroin, or fentanyl: victim unresponsive( ± breathing)
Slide 17: NARCAN Nasal Spray is the only FDA-approved naloxone nasal spray
17 NARCAN® Nasal Spray is the only FDA - approved naloxone nasal spray for reversal of opioid overdose • Developed by Opiant • 2 doses now FDA approved • 6 FDA Orange Book patents • Licensed to Adapt Pharma in 2014 • Partial monetization deal with SWK: • OPNT received $17.5M, SWK receive next $26.25
Slide 18: NARCAN Nasal Spray: rapid absorption with higher blood levels
18 NARCAN® Nasal Spray: Rapid absorption with higher blood levels compared to 0.4mg injectable naloxone Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Slide 19: NARCAN Nasal Spray: easiest to use, needle free
19 NARCAN® Nasal Spray – Easiest to use, needle free and among the least expensive Injectable Naloxone Autoinjectors Improvised Nasal Kits NARCAN® Nasal Spray • Only suitable for trained personnel • Requires prep time • Requires a needle • Expensive • Not needle free • Only suitable for trained pers
Slide 20: Potential $2B addressable market in U.S.
20 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. *Opiant estimate of average selling price ** Co - prescribing starting to happen – mandatory in Vermont for high risk patients First Responders 1M patients with opioid use disorder taking methadone, suboxo
Slide 21: NARCAN Nasal Spray becoming the mainstream rescue product
21 NARCAN® Nasal Spray is becoming the mainstream rescue product across the USA
Slide 22: Beyond Overdose: Addressing Chronic Treatment of Addictions
Beyond Overdose … .Addressing Chronic Treatment of Addictions 22
Slide 23: Leveraging NARCAN success to address larger addiction markets
Opiant is leveraging NARCAN® success to address larger, broader addiction markets 12M 1.5M Opioid Overdose ~33k deaths per year Alcohol Use Disorder ~16 million Eating Disorders ~10 million Opioid Use Disorder ~2.4 million ACUTE CHRONIC 23
Slide 24: OPNT002 for Alcohol Use Disorder (AUD)
OPNT002 for Alcohol Use Disorder (AUD) 24
Slide 25: Today's AUD medication requires abstinence and is poorly tolerated
Today’s AUD medication requires abstinence and is poorly tolerated, so fewer than 5% of receive pharmacotherapy 25 patients with AUD currently receiving pharmacotherapy patients with AUD seeking treatment individuals in the USA meeting DSM - V diagnostic criteria for AUD 2.2M 15.7M 0.4M More effecti
Slide 26: OPNT002 will be a differentiated product for AUD
Combining targeted dosing with a harm reduction endpoint, OPNT002 will be a differentiated product for AUD 26 Need for abstinence prior to commencing medication Need for abstinence as only acceptable outcome Low adherence for existing medication OPNT002 taken whenever patients have the urge to drink
Slide 27: Faster nasal absorption vs oral
Faster nasal absorption vs oral Absorption of oral naltrexone is minimal at 5 - 10 minutes Rapid nasal absorption Vs oral, ensures that the maximum amount of drug is present when it is most needed 27 • Opioid receptors blocked when drinking alcohol • Patients can reduce heavy drinking Naltrexone blo
Slide 28: Existing pharmacotherapies for AUD have limitations
28 OPNT Existing Pharmacotherapies Criteria NASAL Naltrexone OPNT002 * Acamprosate (CAMPRAL) Disulfiram (ANTABUSE) Naltrexone HCl (Oral: ReVia ® / Generics) Naltrexone HCl (Injection: Vivitrol ®) “As - needed” use basis ✔ ✘ ✘ Can be used this way, but not current US practice ✘ Well - tolerated ✔ ✔ ✘
Slide 29: Reduction in drinking is now an acceptable FDA outcome measure
29 Reduction in drinking improves mortality and is now an acceptable outcome measure for FDA approval
Slide 30: OPNT002 can transform AUD treatment and access
Taken as needed, avoiding detox, OPNT002 can transform AUD treatment & access AUD patients in several settings 30 Avoids the need for detox, withdrawal Patients take the drug when needed – greater control over drinking Reduce drinking rather than abstinence (accepted by FDA, KOLs) AUD patients in tr
Slide 31: FDA feedback supportive of OPNT002 development plan
31 FDA feedback supportive of OPNT002 development plan alongside attractive commercial opportunity • Further development planned for 2H 2017 • 505(b)(2) regulatory pathway confirmed – increased likelihood and speed for FDA approval • Potential to self - commercialize and target treatment centers • M
Slide 32: OPNT001 for Eating Disorders
OPNT001 for Eating Disorders 32
Slide 33: Eating disorders affect millions with only one drug approved per indication
Eating disorders affect millions with only one drug approved in each indication 33 Bulimia Nervosa • Compulsive bingeing and purging • Severe complications if untreated • Fluoxetine only approved drug • Affects 2.5M people in USA • Mostly young women Binge Eating Disorder • Most common eating disord
Slide 34: OPNT001 shows promise for Binge Eating Disorder
164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 OPNT001 shows promise for Binge Eating Disorder 34 Proof of concept study (Helsinki) • (n=127) in patients with BED, Randomized, double blind, placebo controlled study • Significant reduction fro
Slide 35: OPNT001 Phase 2 trial design for Bulimia Nervosa
OPNT001 Phase 2 trial design for Bulimia Nervosa 35 • Randomized, double blind, placebo controlled study in the UK underway • 80 patients • Primary endpoint – reduction in binge eating days • Expected duration – 12 months (further guidance once patient recruitment underway) • Data readout expected Q
Slide 36: Corporate
Corporate @ Opiant
Slide 37: Corporate/Clinical Milestones
37 Corporate/Clinical Milestones Enhance corporate governance through establishment of Board committees (1Q 2017) Initiate of Phase 2 trial of OPNT001 in Bulimia Nervosa (2Q 2017) Listed on Nasdaq Capital Market Strengthen management team through appointment of a CSO (1Q 2017) Ongoing development of
Slide 38: OPNT: Investment Highlights
38 OPNT: Investment Highlights Record of commercialization in addiction, where others have failed High value pipeline, clinical and regulatory success in developing nasally - delivered opioid antagonists Significant competitive advantages and strong IP Strong partnerships and strengthened balance sh
Slide 39: Focused on Addiction
FOCUSED ON ADDICTION www.opiant.com
Opiant Pharmaceuticals — Investor Presentation (September 2017) on 6ix